Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;9(1):249-259.
doi: 10.1007/s13346-018-00602-1.

Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis

Prakash Kumar  1 , Partha Pratim Bose  2
Affiliations

Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis

Prakash Kumar et al. Drug Deliv Transl Res. 2019 Feb.

Abstract

Leishmania donovani, an intracellular parasite, poses many challenges against attempted chemotherapy. After the resistance towards the first-line antileishmanial drug, amphotericin B has become the treatment of choice against visceral leishmaniasis, a fatal tropical disease. However, unfavorable toxicity profile, severe side effects, and prolonged parenteral administration limit its use. Lack of available specific delivery system also makes this drug unsafe for long-term use. In the current study, a "ghost cell" strategy based on macrophage membrane-derived nanovesicle has been introduced as a specific carriage for amphotericin B. Membrane proteins of macrophage ghost play a crucial role in the dissemination of infection in host by communicating between infected neutrophil-macrophage system and non-infected macrophages. These membrane proteins are the basis of specificity of the drug delivery to the infected tissues in this current macrophage ghost cell carrier. This cheap and biocompatible delivery vehicle has significantly improved the toxicity profile and lowered LD50 value of the drug compared to traditional way of its direct administration and widely accepted antileishmanial therapy, AmBisome.

Keywords: Amphotericin B; Drug delivery; Macrophage ghost; Membrane-derived vesicle; Visceral leishmaniasis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parasite Immunol. 2013 Jul;35(7-8):239-44 - PubMed
    1. Cell. 2002 Jul 12;110(1):119-31 - PubMed
    1. PLoS One. 2018 Mar 14;13(3):e0193601 - PubMed
    1. Clin Infect Dis. 2000 Oct;31(4):1104-7 - PubMed
    1. Front Cell Infect Microbiol. 2012 Jun 12;2:83 - PubMed

Publication types

LinkOut - more resources